ANN ARBOR, Mich., April 16, 2009 — Lycera Corp. today announced it has closed a $36 million Series A financing. The company, which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a first tranche of the financing and will receive the… Read More

ANN ARBOR, Mich., August 4, 2008 — Lycera Corporation today announced that it entered into a licensing agreement with a leading specialty pharmaceutical company in the United States to develop and commercialize a series of novel small molecules for the topical treatment of human dermal conditions, including mild to moderate psoriasis. According to the National… Read More

ANN ARBOR, Michigan – EDF Ventures today announced the successful completion of venture funding for Lycera Corporation, a pharmaceutical research and development company created in August 2006. The financing was led by EDF Ventures with the participation of a select group of experienced east coast angel investors. Lycera is developing breakthrough small molecule drugs for the treatment of diseases characterized… Read More

Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase… Read More

Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423… Read More